Plain-English translation of NCT06939127 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for a type of lung cancer called non-small cell lung cancer that hasn't spread widely. The study combines three things: cryoablation (freezing the tumor), a medication called tislelizumab (which helps your immune system fight cancer), and chemotherapy. You would receive these treatments before surgery to shrink the tumor, then have surgery to remove it, and then continue with the medication afterward to help prevent the cancer from coming back.
Currently, people with this stage of lung cancer typically receive chemotherapy before surgery. Researchers believe that adding tumor freezing and this new immunotherapy medication might work better than chemotherapy alone to control the cancer and improve survival.
You likely qualify if…
You likely don't qualify if…
First, you would have a procedure called cryoablation to freeze your tumor. About a week later, you would start receiving the medication and chemotherapy together, given as infusions every 3 weeks for 3 to 4 rounds. Within 4 to 6 weeks after your last chemotherapy dose, you would have surgery to remove the treated tumor. After you recover from surgery, you would begin receiving the medication alone (without chemotherapy) as an infusion every 6 weeks for up to 8 more treatments, with regular clinic visits to monitor your health and watch for side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China